Loss of TRIM29 mitigates viral myocarditis by attenuating PERK-driven ER stress response in male mice

Junying Wang1, Wenting Lu1, Jerry Zhang1

  • 1Department of Surgery and Immunobiology and Transplant Science Center, Houston Methodist Research Institute, Houston Methodist, Houston, TX, 77030, USA.

Nature Communications
|April 25, 2024
PubMed

Insights

Viral myocarditis is worsened by TRIM29, which triggers endoplasmic reticulum (ER) stress and inflammation. Targeting the TRIM29-PERK pathway with GSK2656157 protects against this heart disease.

Area of Science:

  • Cardiology
  • Virology
  • Immunology

Background:

  • Viral myocarditis is a serious condition causing sudden death in young individuals.
  • Understanding viral myocarditis pathogenesis is crucial, especially during the COVID-19 pandemic.

Purpose of the Study:

  • To investigate the role of TRIM29 in viral myocarditis.
  • To explore the TRIM29-PERK signaling pathway in cardiac cells and its therapeutic potential.

Main Methods:

  • In vitro studies using cardiomyocytes to assess viral induction of TRIM29 and its effects on ER stress, apoptosis, and ROS.
  • In vivo studies using mouse models of viral myocarditis to evaluate the impact of TRIM29 deficiency and PERK inhibition.
  • Mechanistic studies involving protein interaction and SUMOylation assays to elucidate the TRIM29-PERK relationship.

Main Results:

  • Cardiotropic viruses induce TRIM29, promoting PERK-mediated ER stress, apoptosis, ROS, and viral replication in cardiomyocytes.
  • TRIM29 deficiency protected mice from viral myocarditis by enhancing cardiac antiviral functions and reducing inflammation and immunosuppressive mMDSC.
  • TRIM29 stabilizes PERK via SUMOylation, enhancing PERK-mediated signaling.

Conclusions:

  • Cardiotropic viruses exploit the TRIM29-PERK axis to cause viral myocarditis.
  • Targeting the TRIM29-PERK interaction with inhibitors like GSK2656157 may be a viable therapeutic strategy for viral myocarditis.